陈杰 at BioVenture has developed a distinctive "ten principles" screening framework and "dimensional reduction attack" organizational structure where senior partners work directly as analysts on early-stage projects, creating unusually rigorous due diligence processes in healthcare investing. He maintains balanced exposure across four biotech sectors with active rotation based on valuation cycles, and has spent over a decade tracking emerging fields like stem cell therapy before making investments, demonstrating exceptional patience compared to typical early-stage VCs.